Gilead's Yeztugo Launch Shows Mix of Perspectives, RBC Says

MT Newswires Live04-17

Gilead Sciences' (GILD) Yeztugo launch is off to a solid start, though not tracking towards a transformational prospect, RBC Capital Markets said in a Friday note.

Yeztugo is a prescription medicine used as HIV-1 pre-exposure prophylaxis to reduce the risk of getting HIV-1.

The report said feedback from a mini symposium, key opinion leaders and a payer showed a largely positive experience and improving access while noting challenges in catalyzing overall pre-exposure prophylaxis growth, and early bolus could slow.

"Overall, Yeztugo launch feels solid early, akin to a better Apretude...but not necessarily the mass-market transformational prophylactic we believe was initially hoped for," the report said.

The note added that this is likely reflected in consensus' $7 billion peak sales estimate and in its shares.

RBC kept its sector perform rating with a price target of $123.

Price: 137.88, Change: -0.67, Percent Change: -0.48

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2628200971?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-17 23:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2628200971","market":"us","top_or_hot":-1,"title":"Gilead's Yeztugo Launch Shows Mix of Perspectives, RBC Says","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/GILD\">Gilead</a> Sciences' (GILD) Yeztugo launch is off to a solid start, though not tracking towards a transformational prospect, RBC Capital Markets said in a Friday note.</p><p>Yeztugo is a prescription medicine used as HIV-1 pre-exposure prophylaxis to reduce the risk of getting HIV-1.</p><p>The report said feedback from a mini symposium, key opinion leaders and a payer showed a largely positive experience and improving access while noting challenges in catalyzing overall pre-exposure prophylaxis growth, and early bolus could slow.</p><p>\"Overall, Yeztugo launch feels solid early, akin to a better Apretude...but not necessarily the mass-market transformational prophylactic we believe was initially hoped for,\" the report said.</p><p>The note added that this is likely reflected in consensus' $7 billion peak sales estimate and in its shares.</p><p>RBC kept its sector perform rating with a price target of $123.</p><p>Price: 137.88, Change: -0.67, Percent Change: -0.48</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead's Yeztugo Launch Shows Mix of Perspectives, RBC Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead's Yeztugo Launch Shows Mix of Perspectives, RBC Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-04-17 23:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/GILD\">Gilead</a> Sciences' (GILD) Yeztugo launch is off to a solid start, though not tracking towards a transformational prospect, RBC Capital Markets said in a Friday note.</p><p>Yeztugo is a prescription medicine used as HIV-1 pre-exposure prophylaxis to reduce the risk of getting HIV-1.</p><p>The report said feedback from a mini symposium, key opinion leaders and a payer showed a largely positive experience and improving access while noting challenges in catalyzing overall pre-exposure prophylaxis growth, and early bolus could slow.</p><p>\"Overall, Yeztugo launch feels solid early, akin to a better Apretude...but not necessarily the mass-market transformational prophylactic we believe was initially hoped for,\" the report said.</p><p>The note added that this is likely reflected in consensus' $7 billion peak sales estimate and in its shares.</p><p>RBC kept its sector perform rating with a price target of $123.</p><p>Price: 137.88, Change: -0.67, Percent Change: -0.48</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0965508806.USD","symbol_name":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (USD) INC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2628200971","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2628200971","pubTimestamp":1776439059,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Gilead Sciences'  Yeztugo launch is off to a solid start, though not tracking towards a transformational prospect, RBC Capital Markets said in a Friday note.Yeztugo is a prescription medicine used as HIV-1 pre-exposure prophylaxis to reduce the risk of getting HIV-1.The report said feedback from a mini symposium, key opinion leaders and a payer showed a largely positive experience and improving access while noting challenges in catalyzing overall pre-exposure prophylaxis growth, and early bolus could slow.\"Overall, Yeztugo launch feels solid early, akin to a better Apretude...but not necessarily the mass-market transformational prophylactic we believe was initially hoped for,\" the report said.The note added that this is likely reflected in consensus' $7 billion peak sales estimate and in its shares.RBC kept its sector perform rating with a price target of $123.Price: 137.88, Change: -0.67, Percent Change: -0.48","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0965508806.USD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (USD) INC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU1934455277.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"AD\" (USD) INC","BK4568":"美国抗疫概念","BK4588":"碎股","BK4550":"红杉资本持仓","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU1037948541.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (HKD) ACC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","LU1674673428.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AC\" (USD) ACC","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC","LU1934455194.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (USD) ACC","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","BK4583":"猴痘概念","LU1934455863.HKD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (HKD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","GILD":"吉利德科学","BK4532":"文艺复兴科技持仓","LU0965509101.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (SGDHDG) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU0882574055.USD":"富达全球健康医疗A ACC","LU2087621335.USD":"ALLSPRING GLOBAL FACTOR ENHANCED EQUITY \"A\" (USD) ACC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0861579265.USD":"联博低波幅策略股票基金A","BK4585":"ETF&股票定投概念","LU0122379950.USD":"贝莱德世界健康科学A2","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","BK4139":"生物科技","LU1037948897.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (HKD) INC","LU1778281490.HKD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (HKD) INC","LU0058720904.USD":"联博国际健康护理基金A","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","BK4566":"资本集团","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","BK4578":"CAR-T","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H"},"translate_title":"加拿大皇家银行表示，吉利德的Yeztugo推出显示了多种观点","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GILD":1},"content_text":"Gilead Sciences' (GILD) Yeztugo launch is off to a solid start, though not tracking towards a transformational prospect, RBC Capital Markets said in a Friday note.Yeztugo is a prescription medicine used as HIV-1 pre-exposure prophylaxis to reduce the risk of getting HIV-1.The report said feedback from a mini symposium, key opinion leaders and a payer showed a largely positive experience and improving access while noting challenges in catalyzing overall pre-exposure prophylaxis growth, and early bolus could slow.\"Overall, Yeztugo launch feels solid early, akin to a better Apretude...but not necessarily the mass-market transformational prophylactic we believe was initially hoped for,\" the report said.The note added that this is likely reflected in consensus' $7 billion peak sales estimate and in its shares.RBC kept its sector perform rating with a price target of $123.Price: 137.88, Change: -0.67, Percent Change: -0.48","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2628200971","isCrawlerRequest":true}